Clinical Trial

Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a neuroprotective role on the basis of intravenous thrombolysis therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of Shuxuening injection in the treatment with intravenous thrombolysis in patients with ischemic stroke.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-11-27; most recent amendment 2025-07-21.
Status change: Not Yet Recruiting → Recruiting 2024-02-04
Trial Details
NCT Number NCT06157502
Lead Sponsor Beijing Tiantan Hospital
Conditions Ischemic Stroke, Acute
Enrollment 1,380 participants
Start Date 2024-01-11
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-24